Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort

BACKGROUND: Protease inhibitors (PI) including boceprevir, telaprevir and simeprevir have revolutionised HCV genotype 1 treatment since their introduction. A number of pre-treatment resistance associated amino acid variants (RAVs) and polymorphisms have been associated with reduced response to treat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Virol
Asıl Yazarlar: Shepherd, Samantha J., Abdelrahman, Tamer, MacLean, Alasdair R., Thomson, Emma C., Aitken, Celia, Gunson, Rory N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier Science 2015
Konular:
Short Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4728298/
https://ncbi.nlm.nih.gov/pubmed/25766988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcv.2015.02.005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller